^
    Back
    Association details:
    Biomarker:ACSL4 overexpression
    Cancer:Breast Cancer
    Drug:cisplatin (DNA synthesis inhibitor) +
    albumin-bound paclitaxel (Bcl2 inhibitor, Tubulin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Lancet
    Title:

    Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy

    Published date:
    09/01/2021
    Excerpt:
    This study included patients treated with paclitaxel-cisplatin-based neoadjuvant chemotherapy...Analyses of the Kaplan-Meier Plotter database suggested that higher ACSL4 expression is related to better overall survival, and higher GPX4 expression is related to better distant metastasis-free survival.
    DOI:
    https://doi.org/10.1016/j.ebiom.2021.103560